Genomic Epidemiology of *Enterococcus faecium* Bloodstream Infections During a VanB-type VRE Peak Reveals an Oligoclonal Scenario: An Observational Study at a German University Hospital (2017–2022)

Leonard Knegendorf [1,2], Anna Sommer [3,4], Claas Baier [1,5], Robert E. Weber [3,4], Martin A. Fischer [3,4], Guido Werner [3,4], Stefan Ziesing [1], Dirk Schlüter [1,6]

1 Hannover Medical School (MHH), Institute for Medical Microbiology and Hospital Epidemiology, Hannover, Germany

2 TWINCORE Centre for Experimental and Clinical Infection Research, Institute for Molecular Bacteriology, Hannover, Germany

3 Robert Koch Institute, Department of Infectious Diseases, Wernigerode Branch, Wernigerode, Germany

4 National Reference Centre for Staphylococci and Enterococci, Wernigerode, Germany

5 Infection Prevention and Control Department, Agaplesion Diakonieklinikum Rotenburg, Rotenburg (Wümme), Germany

6 Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany

Leonard Knegendorf and Anna Sommer contributed equally as first authors. The order of names is alphabetical.

Address correspondence to Leonard Knegendorf, Knegendorf.Leonard@mh-hannover.de

Running Title: Oligoclonal *vanB*-type VRE in Bloodstream Infections

Keywords: Enterococcus faecium, vancomycin resistance, bloodstream infection, genomic epidemiology, split k-mer analysis

Conflict of interest: The authors declare no conflict of interest.

Abstract

Background: A substantial and rapid increase, followed by a sharp decline in *vanB*-type vancomycin-resistant *E. faecium* (VRE), occurred in Germany in the late 2010s. This unusual epidemiological trend prompted detailed genomic investigations to explore the underlying dynamics at a German university hospital.

Methods: We retrospectively analyzed *E. faecium* bloodstream infection (BSI) isolates collected between 2017 and 2022. Isolates were classified as *vanA*-positive, *vanB*-positive, or *van*-negative. Molecular typing included multilocus sequence typing (MLST), core genome MLST (cgMLST), and split k-mer analysis (SKA). Clonal relationships and potential patient-to-patient transmission events were assessed by integrating genomic data with machine-aided analysis of available longitudinal patient movement data.

Results: High-resolution genomic analysis of BSI isolates revealed an oligoclonal scenario involving multiple epidemic lineages (e.g., sequence type (ST)117/complex type (CT)71, ST117/CT929, ST117/CT2505, ST80, and ST262) with distinct *van* genotypes and dynamic changes over time. Overall, genomic overlap between *vanA*-positive, *vanB*-positive, and *van*-negative populations was minimal. The *vanB* surge, peaking in late 2018-early 2019, was mainly driven by ST117/CT71, ST117/CT36, and ST117/CT1917. SKA provided enhanced discriminatory power over cgMLST. Prolonged intervals between infection onsets and frequent intra-hospital transfers were characteristic of potential transmission events.

Conclusions: Accurate characterization of the transient *vanB*-type VRE peak required an integrated genomic approach combining cgMLST, high-resolution SKA, and epidemiological data. These comprehensive methods enable infection prevention and control (IPC) teams to distinguish true outbreaks from numerical clusters of polyclonal isolates. This allows for accurate interpretation and precisely targeted interventions where evidence supports transmission.

Word count abstract: 241

Importance

Vancomycin-resistant *Enterococcus faecium* is an increasingly important nosocomial pathogen worldwide. Understanding its epidemiology and transmission dynamics is critical to effectively control its spread. This study documents shifting *E. faecium* populations within a high-risk hospital environment, including both vancomycin-resistant and vancomycin-susceptible bloodstream isolates. Detailed genomic analyses, combining core genome multilocus sequence typing with high-resolution split k-mer analysis, integrated with comprehensive epidemiological tracking, were critical to accurately depict complex epidemiological dynamics. This combined approach allows precise differentiation between monoclonal outbreaks and oligoclonal transmission, enabling more targeted infection prevention and control strategies.

Introduction

Enterococci are commensals of the human intestinal microbiome. Under certain conditions, however, they can also cause infections, particularly in immunocompromised and critically ill patients. They are a significant cause of nosocomial bloodstream infections. Of the many known *Enterococcus* species, only two are of major medical significance: *Enterococcus faecium* and *E. faecalis*. In particular, *E. faecium* isolates are characterized by high environmental resistance, an enhanced tolerance to disinfectants, and a wide range of acquired antibiotic resistances (1, 2). Hospital-associated isolates of this species differ from those colonizing the intestines of humans and animals. Genome comparisons show that infectious isolates fall into three distinct genomic clades called A1, A2, and B (3), whereas human commensal isolates of clade B are suggested to be reassigned to another species called *E. lactis* (4, 5).

Vancomycin is a first-line agent for the treatment of infections caused by enterococci, particularly *E. faecium*. Acquired resistance to vancomycin primarily occurs in members of the species *E. faecium* and to a much lesser extent in *E. faecalis*. Of the eight different variants of acquired vancomycin resistance, the *vanA* and *vanB* variants are of major medical importance. The *vanA* gene cluster is predominantly localized on plasmids that can be transferred between different strains. In contrast, the *vanB* gene cluster is mainly part of the bacterial chromosome, but can also be conjugated between different strains (6, 7). Both types of acquired vancomycin resistance could be transferred by clonal expansion or horizontal transfer.

Both national and international surveillance programs and schemes report comparably high rates of VRE in Germany. While VRE-BSI showed a rapid increase up until 2020, more recent data indicate a subsequent decline in case numbers (8). Data from the National Reference Centre for Enterococci,

along with various publications on patient-associated enterococci, confirm the predominant prevalence of *vanB*-type VRE in Germany during the increase in VRE-BSI up to 2020.

The incidence of VRE BSI in Germany is relatively low, but it doubled from 1.7 to a peak of 3.0 per 100,000 in 2021 before declining back to 1.7 in 2023 (8). It ranges from 0.1% to 10.6% in high-risk hospitalized patients (9). Whole-genome sequencing (WGS) enables detailed strain classification, with MLST assigning a sequence type (ST) from allelic profiles of seven housekeeping genes and cgMLST assigning a complex type (CT) from the unique combination of alleles across 1,423 conserved loci (10).

Genomic analyses of local and regional invasive VRE strains in Germany from 2010 to 2020 revealed the preferential spread of certain strain variants associated with *vanB*-type resistance. For instance, *E. faecium* isolates of ST117/CT71/*vanB* were found to be widespread throughout Germany, whereas isolates of ST80/CT1065/*vanB* predominantly spread regionally focusing on southern and western Germany (11). Local outbreaks may be dominated by unique strain types such as ST80/CT1013/*vanB* as recently described (12).

In this study, we retrospectively analyzed *E. faecium* isolates from BSIs in patients treated at Hannover Medical School, a 1,500-bed tertiary university hospital in northern Germany that specializes, among other areas, in solid-organ transplantation. The isolates were collected from 2017 to 2022 to cover the observed increase and decrease of VRE prevalence in Germany as well as the impact of the SARS-CoV-2 pandemic. Isolates underwent WGS and molecular typing, followed by epidemiological tracking of phylogenetically related strains to gain a deeper understanding of *E. faecium* epidemiology.

Materials and Methods

Clinical Case Definition

From October 11, 2017, to February 10, 2022, we included every *E. faecium* isolate from blood cultures for which antimicrobial susceptibility testing was performed in routine diagnostics. We included at least one strain per patient as well as strains with distinct colony morphology or isolated more than seven days after the initial isolate. We performed retrospective identification of isolates by querying the laboratory information system database (M/Lab, DORNER Health IT Solutions, Müllheim, Germany) and manually reviewing available isolates in our strain collections, which the laboratory routinely maintains. The isolates originated from various hospital wards, including the pediatric clinics, thus ensuring a comprehensive representation across different clinical settings. Throughout the study period, all patients who tested positive for VRE were isolated in single rooms or cohorted, and staff wore personal protective equipment (gowns and gloves).

Ethics committee of Hannover Medical School gave ethical approval for this work (No. 10388_BO_K_2022). Since this was a retrospective quality-assuring study, Ethics Committee and Data Protection Commissioner of Hannover Medical School waived the need for informed consent.

Bacterial Isolates and Susceptibility Testing

Blood samples were inoculated in BD BACTEC™ Plus Aerobic and BD BACTEC™ Lytic Anaerobic culture vials (BD, Heidelberg, Germany) and incubated in a BD BACTEC™ FX system according to the manufacturer's instructions. When flagged positive, blood culture samples were subcultured on solid media following internal laboratory protocols. Species identification was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) with a Vitek MS system (bioMérieux, Marcy-l'Étoile, France). Antimicrobial susceptibility testing (AST) was conducted with a Vitek 2 system (bioMérieux, Marcy-l'Étoile, France). A VRE was identified when the isolate tested resistant to vancomycin according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints that were valid for the respective year of the study. Furthermore, a VanA phenotype was characterized by resistance to vancomycin and teicoplanin, while a VanB phenotype was characterized by resistance to vancomycin, and susceptibility to teicoplanin. Bacterial strains were stored in tryptone soy broth (Oxoid, Wesel, Germany) supplemented with 30% glycerine (CHEMSOLUTE©, Th. Geyer, Renningen, Germany) and kept at -80°C until whole-genome sequencing.

Whole-genome Sequencing, Quality Control and Genome Reconstruction

Bacterial cultures were grown in Brain Heart Infusion (BHI) broth. Genomic DNA was extracted from an overnight culture using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany). DNA concentration was quantified with the Qubit dsDNA HS Assay Kit on a Qubit 4 Fluorometer (Thermo Fisher Scientific, Karlsruhe, Germany). Sequencing libraries were prepared using the Nextera XT DNA Library Preparation Kit (Illumina, San Diego, CA, United States), and paired-end sequencing was conducted on a NextSeq instrument with a read length of 150 bp (Illumina, San Diego, CA, United States). Raw sequence data quality was assessed using FQStat v0.0.12 (13), FastQC v0.12.1 (Andrews *et al*., https://www.bioinformatics.babraham.ac.uk/projects/fastqc/), AQUAMIS v1.3.12 (14) and SeqSphere^{+} v9.0.10 (Ridom, Münster, Germany). Eleven of 344 isolates were excluded due to inadequate quality control parameters and were not included in further analyses. These included six with AQUAMIS failure, one with <95% good cgMLST targets, and four due to multiple reasons including AQUAMIS failure. After quality control, Illumina raw reads were *de novo* assembled using SPAdes v3.14.1 with default parameters (15).

Resistance Gene Identification

The identification of the glycopeptide resistance genes *vanA* and *vanB* was performed using *de novo* assembled contigs with CLC Genomics Workbench v24.0.1 and the 'Find Resistance with Nucleotide Database' tool utilizing the QMI-AR Nucleotide Database.

Molecular Typing

MLST and cgMLST were carried out using established typing schemes in Ridom SeqSphere+ v9.0.10 (10, 16). Based on cgMLST, a Minimum Spanning Tree (MST) was inferred using the option 'pairwise ignoring missing values'. CgMLST clusters were then defined by a pairwise allelic difference threshold of ≤15 alleles. In addition to cgMLST, split k-mer analysis (SKA) version 1.0 was performed with a k-mer size of 15, a SNP cutoff of 7, and an identity cutoff of 0.9 (17).

Epidemiological Analysis

For in-depth epidemiological analysis, we manually extracted data on patient movements from the hospital information system. Only inpatient stays were considered, and the analysis was limited to the ward level. An epidemiological link was defined as two patients having overnight stays on the same ward within a rolling 30-day window, with both stays preceding detection of the secondary patient's bloodstream isolate. Cases that did not meet this criterion were not considered epidemiologically linked. To systematically identify such links, a machine-aided approach was implemented using Python (v3.13.3) and pandas (v2.2.3). We programmatically queried patient movement data to identify qualifying patient-to-patient contacts based on the defined criteria and the sampling dates of the corresponding bloodstream isolates.

To aid the interpretation of potential transmission routes, we stratified clinical departments into three specialty groups based on the organ systems predominantly treated: (i) hematopoietic system, including hematology-oncology and hematopoietic stem cell transplantation units; (ii) excretory system, encompassing gastroenterology, hepatology, nephrology, urology, visceral surgery, and related fields; and (iii) respiratory and cardiovascular system, including pneumology, cardiology, cardiac surgery, and associated specialties. These groupings were used to reflect likely overlap in patient pathways and potential transmission reservoirs across functionally related wards. Departments that did not clearly align with one of these three categories were assigned to an "Other" group. In cases where patients were treated in interdisciplinary intensive care units, stratification was based on the underlying disease rather than the unit type.

Statistical analysis was performed using GraphPad Prism v10.5.0 (GraphPad Software, Boston, MA, United States).

Results

The Rise and Fall of VanB type VRE at MHH

The prevalence of VRE in patients at Hannover Medical School was assessed from 2013 to 2024_1 (suffix _1/_2 = first/second half-year). Following a sharp increase beginning in 2017 and peaking in 2019, the absolute number of patients with the VanB phenotype steadily declined, reaching pre-2017 levels by 2022. This downward trend began well before the overall decline in cases treated at the hospital, which was largely attributable to the COVID-19 pandemic. In contrast, the number of VRE patients with the VanA phenotype has remained largely constant throughout the period (Fig. 1).

Isolate Collection Strategy

To analyze the temporal dynamics and genotype of *E. faecium* strains causing invasive disease, we only included *E. faecium* strains isolated from blood cultures between 2017 and 2022. Of 414 isolates (98 VRE, 316 vancomycin-susceptible (VSE)), 344 underwent whole-genome sequencing. Following quality control, 333 isolates (80.43%) were included in the final analysis (Fig. 2A). The annual distribution of *E. faecium* isolates showed considerable variation, with the highest count recorded in 2021 (2017: n=5, 2018: n=61, 2019: n=52, 2020: n=92, 2021: n=102, and 2022: n=21; Fig. 2B). Among the isolates, 238 did not carry any *van* resistance genes, while 19 were positive for *vanA* and 76 for *vanB*. Notably, three of the 19 isolates carrying *vanA* and eight of the 76 isolates carrying *vanB* genes were phenotypically susceptible to vancomycin (Table S1). Due to the presence of the corresponding resistance determinants, the isolates were classified as VRE. For subsequent population analysis, duplicate isolates were excluded (same patient, same CT).

Temporal shifts in clonal lineages and *van*-genotype prevalence

Population analysis based on MLST and cgMLST revealed temporal variations in the distribution of specific STs/CTs over time, with certain lineages, such as ST117/CT71/*vanB* and ST117/CT929/*van*-negative, persisting throughout the study period (Fig. 3A/B). From 2019 onward, however, ST117/CT71/*vanB* declined yet remained detectable, whereas ST117/CT929/*van*-negative and ST117/CT2505, *van*-negative and *vanA* variants, became increasingly prevalent in the following years.

The proportion of isolates with *vanA, vanB*, and *van*-negative genotypes varied throughout the study period. *Van*-negative isolates consistently accounted for the majority of analyzed isolates, with an increasing trend until 2021 (Fig. 3C). In this cohort, *vanA*-positive BSI isolates first appeared in 2019

and remained at low, fluctuating levels thereafter. After maintaining a stable prevalence of 30-40%, *vanB*-positive *E. faecium* BSI isolates declined sharply from the second half of 2019 (2019_2) onward to approximately 10% in subsequent years.

A detailed analysis of the total number of isolates for each *van*-genotype underscores the contribution of certain clonal lineages – such as ST117/CT71, ST117/CT36, and ST117/CT1917 – to the prevalence of *vanB*-positive isolates (Fig. 3D). These clonal types were particularly prevalent during the second half of 2018 (2018_2) and the first half of 2019 (2019_1; Fig. 1, Fig. 3B/3D). Among the *van*-negative isolates, ST117/CT929 was the most dominant, followed by ST80 (17 CTs, chiefly CT467 and CT1470) and ST117/CT2505. Notably, *vanA*-positive isolates were rare and primarily detected in ST80/CT1470.

Prevalence of *van* genotypes across diverse cgMLST clusters

An MST was generated using cgMLST with a cluster threshold of ≤15 alleles difference. The total of 333 isolates was grouped into 17 distinct clusters, while 50 isolates remained as singletons (i.e., isolates not grouped into a cluster; Fig. 4A). Four out of the 17 clusters were designated major cgMLST clusters, which included the predominant clones ST117/CT929 and ST117/CT2505 (Cluster 1, n=111), ST117/CT71 (Cluster 2, n=47), ST80/CT467 (Cluster 3, n=23), and ST80/CT1470 (Cluster 4, n=15). In line with the analysis of *van* genotypes (Fig. 4D), Cluster 1 is primarily composed of *van*-negative *E. faecium* isolates, whereas Cluster 2 is largely associated with *vanB*-carrying variants (Fig. 4B). Although *vanA* was found in various clusters, Cluster 4 displayed the highest proportion of *vanA*-positive isolates.

SKA provides higher resolution clustering than cgMLST

The assignment of individual isolates to specific clusters has important implications for the definition of outbreaks, hospital epidemiology, and the respective measures to prevent transmission of enterococci. Therefore, we tested different methods for defining clusters of *E. faecium* isolates, specifically focusing on cgMLST and SKA (Fig. 5). The classification of *E. faecium* isolates follows a stepwise refinement across the applied typing methods, progressively increasing resolution from MLST to cgMLST and SKA (Fig. 5). Starting with MLST, isolates were assigned to 16 STs, with ST117 (n=225), ST80 (n=66), and ST262 (n=16) being the most prevalent. While MLST provides only a broad genetic classification, cgMLST enhances resolution by reassigning the 16 identified STs into 70 CTs. Using a cluster threshold of ≤15 alleles, these 70 CT-defined groups were further consolidated into 20 possibly outbreak-related clusters and 44 singletons (see also Fig. 4). While cgMLST relies on 1,423 core genes, SKA, as a k-mer-based approach, also incorporates the

accessory genome and intergenic regions. Due to this broader genomic inclusion, a considerable number of isolates classified within cgMLST outbreak clusters were reassigned as singletons in the SKA analysis. Using SKA, 40 clusters and 144 singletons were identified. This does not reflect an increase in outbreak-related isolates, but rather a higher-resolution subdivision of previously defined cgMLST clusters.

Longitudinal Analysis of *E. faecium* ST117/CT71 Transmission

Understanding the epidemiological dynamics of *E. faecium* transmission is crucial for identifying potential outbreaks and improving infection control strategies. This analysis focuses on cgMLST cluster 2 (ST117/CT71) as one key driver of the *vanB* peak, examining spatial and temporal relationships to assess potential epidemiologic linkages.

A total of 52 ST117/CT71 isolates, one ST117/CT5101, and one ST117/CT7838 from 47 individual patients constituted the cgMLST cluster 2 (7 patients had two clinical isolates) (Fig. 6A). The majority of patients were treated in one of three organ system-based specialty groups (see Materials and Methods): hematopoietic system, excretory system, or cardiovascular and respiratory system (Fig. S1). Of the 47 patients, 24 (51.1%) had a documented intestinal VRE colonization prior to or at the time of infection. The cluster includes infection isolates from 2017-2022, with affected patients hospitalized across 36 wards.

SKA subdivided cgMLST cluster 2 into eight clusters and 31 singletons (Fig. 6A). Within all SKA clusters, epidemiological links could be detected, and five of the eight SKA clusters showed strong epidemiological linkage indicative of potential transmission (same ward within 30 days; cluster 11, 12, 14, 15, and 16; Fig. 6B). Five isolate pairs originated from the same patient (cluster 11, 12, 15, 17, and 18). We also analyzed available epidemiological data (Fig. S1) for potential links between all isolates in cgMLST cluster 2. Notably, 33 of 47 patients (70.2%) had been admitted to more than two different wards during the study. Our analysis identified 29 patients with epidemiological links within this cluster, despite their isolates being classified as singletons in SKA. Several patients were linked to others either as potential sources or recipients, with some having multiple plausible links, resulting in 55 total links across both SKA-defined clusters and singletons. The median time interval between BSIs across all links was 106 days (95% CI: 59.0-246.0). Notably, links in SKA-defined clusters showed a significantly shorter median interval between BSIs of 22 days compared to 118.5 days for links of SKA singletons (p = 0.0499, two-tailed Mann-Whitney U test).

Discussion

The global emergence and dissemination of VRE remain pressing public health challenges, with notable epidemiological trends documented in Europe and worldwide. Germany experienced a marked increase in VRE cases during the late 2010s (18, 19), primarily driven by the clonal expansion of *vanB*-positive lineages, notably ST117/CT71 (20–22). Similar *vanA* to *vanB* dominance shifts have been observed globally, though circulating clones frequently remain region-specific (11, 23–25).

At Hannover Medical School, VanB-type VRE cases rose sharply between 2017 and 2019, peaked in 2019, then declined significantly and stabilized by 2021. For this study, we performed genomic population analysis on 80.43% of all *E. faecium* BSI isolates meeting the inclusion criteria during the study period, thus providing a robust representation of the clinical population. We identified an overall proportion of 23.67% vancomycin resistance, aligning with European reports (26, 27).

CgMLST analysis revealed that *vanB*-type rise and fall were predominantly associated with ST117/CT71 (31.3% in 2018_2; 21.4% in 2019_1) but also other clonal lineages like ST117/CT36 (14.3% in 2019_1) and ST117/CT1917 (6.3% in 2018_2). This aligns with findings from the National Reference Centre on Enterococci and others, which reported country-wide expansion of ST117/CT71/*vanB* until 2019, followed by significant decline (21, 22, 28). Similarly, Danish surveillance detected the emergence of ST117/CT36 starting in 2019, likely originating from German hospitals (25). Mills *et al.* demonstrated that emergent VRE lineages (ST80, ST117, ST1478) achieve competitive advantage through bacteriocin T8 production, present in 70-96% of emergent lineages but only 16% of others, thereby providing significant colonization advantages *in vivo* (29). The transient dominance of specific clones contrasts with Australian data showing stable virulome and resistome profiles of major clonal lineages over 15 years (30). Collectively, these findings suggest transmission efficiency drives lineage success rather than escalating virulence, consistent with the view that enterococcal virulence factors primarily serve ecological rather than pathogenic roles (31). While VRE now matches methicillin-resistant *Staphylococcus aureus* (MRSA) in disease burden, awareness remains disproportionately focused on MRSA (32).

The *vanB* peak did not coincide with an overall increase in BSIs, suggesting a shift in the underlying population structure – likely due to changes in colonizing strain prevalence – rather than an acute outbreak scenario. From mid-2019 onwards, *van*-negative isolates, primarily ST117/CT929 (33.7% in 2021) and ST117/CT2505 (19.8% in 2021), became increasingly prevalent. These lineages have been identified throughout Germany and rose notably from 2020 onward (28), with a recent study finding clonal isolates of these lineages being vancomycin-resistant (33). Although ST117/CT71/*vanB* isolates decreased significantly after 2019, they persisted throughout the study period. This suggests that there were ongoing transmission chains despite intensified infection control measures during the SARS-CoV-2 pandemic, which were expected to limit nosocomial

transmission in general (34). These transmissions may have originated from environmental reservoirs, within or outside the hospital.

In contrast, *vanA*-type associated BSIs – absent during the peak of *vanB* – emerged from 2019 onward, mainly driven by *vanA*-type ST80 expansion. Recent reports demonstrate rapid national and cross-border dissemination of new *vanA*-positive lineages (25, 35, 36). Alongside the generally more stable prevalence of the VanA phenotype, these observations highlight the complexity of VRE resistance dynamics and underscore the importance of continued molecular surveillance.

Although horizontal transfer of vancomycin-resistance genes in *E. faecium* is possible (7), *van*-positive isolates rarely cluster with *van*-negative isolates, indicating limited transmission of corresponding resistance determinants between vancomycin-resistant and VSE BSI isolates, confirming data from a Danish study covering the years 2015-2019 (37). This is further in accordance with experimental evidence showing no vancomycin resistance transfer *via* membrane vesicles (38) and genomic analyses confirming lineage-specific *vanA*-plasmids (39). Although acquisition of *van* elements to generate novel VRE types might not be a very frequent event, our data showed that it happened occasionally. From an evolutionary perspective, such events, even if they are very rare, may lead to a fast clonal expansion of certain novel strain types that appear by chance, i.e., a "bottleneck effect." In this context, extending genomic surveillance to include susceptible progenitor populations–such as VSE isolates from bloodstream infections, as in our case–has a clear and well-founded rationale.

We identified outbreak clusters using cgMLST with ≤15 alleles threshold (16), revealing four dominant clusters (clusters 1-4). Recent studies advocate stricter clustering thresholds of ≤3 alleles to enhance discriminative power (40, 41); however, this conservative cut-off was derived for short-lived, spatially restricted outbreaks and may be too stringent for prolonged transmission events such as those analyzed here, where epidemiologically and phylogenetically linked cases naturally accumulate polymorphisms over time (42).

High-resolution genomic typing is increasingly recommended for hospital outbreak investigations (40). While cgMLST provides robust initial clustering, SKA enables refined discrimination, as demonstrated by Maechler *et al.* (43). We retrospectively applied SKA to ST117/CT71 isolates (cgMLST cluster 2), the main *vanB* peak driver. SKA resolved cgMLST cluster 2 into eight sub-clusters and 31 singletons, underscoring its high discriminatory power. Only one of eight SKA-defined clusters lacked likely epidemiological connections (either indicative of potential transmission or isolates originating from the same patient). The treating specialties of patients in cgMLST cluster 2 were consistent with previous studies identifying visceral surgery as a risk factor for nosocomial VRE infections (44), and internal medicine as having the highest incidence of VRE BSIs across six German university hospitals (26). Analysis of longitudinal patient-movement data identified epidemiological links involving 29 of 47 patients whose isolates had been classified as SKA

singletons. These epidemiological connections, based on shared ward exposures, would have been difficult to detect manually due to repeated admissions and intra-hospital transfers over extended periods. Notably, isolates classified as SKA singletons exhibited significantly longer median intervals between linked BSI cases compared to isolates within SKA-defined clusters, suggesting that the 7-SNP SKA cutoff may be overly stringent for retrospective population studies involving prolonged transmission intervals. In contrast, the ≤15 allele cgMLST threshold may overestimate relatedness, potentially clustering genetically distinct isolates and generating false positives. Consequently, a tiered approach integrating high-resolution methods (such as SKA), cgMLST clustering, and detailed epidemiological analyses is necessary to balance sensitivity and specificity when investigating potential transmission events. While our findings align with the two-step genomic analysis pipeline proposed by Higgs *et al*. for investigating suspected VRE transmissions in real-time (40), our results highlight the importance of calibrating thresholds to the specific surveillance context.

Several limitations of this study should be acknowledged. Due to its retrospective design, comprehensive assessment of epidemiological links was not possible, particularly with regard to the intestinal colonization status of patients. As a result, we could not determine the number of nosocomially acquired isolates. Furthermore, detailed patient-movement data had to be extracted manually from the hospital information system; to keep the effort within realistic limits, we retrieved these data only for the largest cgMLST cluster (cluster 2), as it was most relevant to the *vanB* peak. Environmental reservoirs (e.g., contamination in bathrooms or on medical equipment), on which VRE can persist for extended periods (45), as well as colonization-only vectors, may have contributed to transmission but could not be systematically investigated. The study was conducted at a single tertiary care center, which may limit the generalizability of the findings to other healthcare settings. In addition, isolate availability varied across study years, particularly in 2019 and 2021, potentially affecting the robustness of the population analysis during these periods.

Despite these limitations, our study demonstrates complex shifts in clonal lineages of *E. faecium* and *van* genotypes at Hannover Medical School. The *vanB* peak observed in 2019 most likely reflected a shift in the overall population structure of *E. faecium*. This shift was evident in the BSI isolates analyzed here, which displayed an oligoclonal pattern dominated by ST117/CT71, along with other *vanB*-positive clonal lineages, such as ST117/CT36 and ST117/CT1917. Of note, we identified clusters of *van*-negative lineages (ST117/CT929 and ST117/CT2505). Such clusters of *van*-negative *E. faecium* may be perceived as less concerning by clinicians due to available treatment options, but they have to be addressed by IPC measures similar to those applied for VRE. In genomic outbreak analysis, SKA and cgMLST provide complementary strengths, but their limitations require careful consideration, as their outcomes have direct implications for outbreak detection, reporting, and management. Adopting an integrated approach combining both methods will enhance genomic surveillance and provide valuable insights to guide targeted infection control strategies.

Data availability

All raw sequencing reads generated in this study have been deposited in the European Nucleotide Archive (ENA) under the project accession number PRJEB91895. Raw data related to the investigation of epidemiological links and additional metadata for the whole-genome sequences cannot be shared publicly, as these data contain confidential patient information protected by the German Data Privacy Act, as well as by the ethics committee and the data protection commissioner of Hannover Medical School. Patient-related data, such as ward of admission, age, sex, underlying disease, or length of stay, are considered indirect identifiers and could enable re-identification of patients. To protect patient confidentiality and participants' privacy, only anonymized and aggregated data can be made available. Researchers who meet the criteria for access to confidential data may request anonymized data by contacting the data protection commissioner of Hannover Medical School (datenschutz@mh-hannover.de) and the corresponding author (knegendorf.leonard@mh-hannover.de). Data sharing is subject to approval by the ethics committee and the data protection commissioner.

Acknowledgements

We thank the healthcare personnel on the wards for obtaining the patient samples, as well as the technical staff of the Institute for Medical Microbiology and Hospital Epidemiology for isolating the clinical strains and maintaining the strain collection. We thank Carola Fleige, Christine Bornstädt and the staff at MF2-Genome Sequencing and Genomic Epidemiology Core of the Robert Koch Institute for excellent technical assistance. We also thank PD Dr. Marius Vital for critically discussing the scope of the study.

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

1. Arias CA, Murray BE. 2012. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol 10:266–278. https://doi.org/10.1038/nrmicro2761.

2. Scharloo F, Cogliati Dezza F, López-Hernández I, Martínez Pérez-Crespo PM, Goikoetxea Aguirre AJ, Pérez-Rodríguez MT, Fernandez-Suarez J, León Jiménez E, Morán Rodríguez MÁ, Fernández-Natal I, Reguera Iglesias JM, Natera Kindelán C, Fariñas Álvares MC, Boix-Palop L, Lopez-Cortes LE, Rodríguez-Baño J, PROBAC/GEIRAS-SEIMC/SAMICEI group, Jover-Sáenz A, Sánchez-Calvo JM, Gea-Lázaro I, Bahamonde Carrasco A, Vinuesa García D, Del Arco Jiménez A, Smithson Amat A, Sánchez Porto A, Pérez Camacho I, Cuquet Pedragosa J, Merino De Lucas E, Becerril Carral B, Martín Aspas A, Reche I. 2024. Clinical characteristics, predisposing factors and outcomes for Enterococcus faecalis versus Enterococcus faecium bloodstream infections: a prospective multicentre cohort study. Eur J Clin Microbiol Infect Dis 43:2011–2022. https://doi.org/10.1007/s10096-024-04917-5.

3. Lebreton F, Van Schaik W, Manson McGuire A, Godfrey P, Griggs A, Mazumdar V, Corander J, Cheng L, Saif S, Young S, Zeng Q, Wortman J, Birren B, Willems RJL, Earl AM, Gilmore MS. 2013. Emergence of Epidemic Multidrug-Resistant Enterococcus faecium from Animal and Commensal Strains. mBio 4:e00534-13. https://doi.org/10.1128/mBio.00534-13.

4. Belloso Daza MV, Cortimiglia C, Bassi D, Cocconcelli PS. 2021. Genome-based studies indicate that the Enterococcus faecium Clade B strains belong to Enterococcus lactis species and lack of the hospital infection associated markers. Int J Syst Evol Microbiol 71. https://doi.org/10.1099/ijsem.0.004948.

5. Ocejo M, Mugica M, Oporto B, Lavín JL, Hurtado A. 2024. Whole-genome long-read sequencing to unveil *Enterococcus* antimicrobial resistance in dairy cattle farms exposed a widespread occurrence of *Enterococcus lactis*. Microbiol Spectr 12:e03672-23. https://doi.org/10.1128/spectrum.03672-23.

6. Arthur M, Courvalin P. 1993. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 37:1563–1571. https://doi.org/10.1128/AAC.37.8.1563.

7. Cetinkaya Y, Falk P, Mayhall CG. 2000. Vancomycin-Resistant Enterococci. Clin Microbiol Rev 13:686–707. https://doi.org/10.1128/CMR.13.4.686.

8. Brinkwirth S, Martins S, Ayobami O, Feig M, Noll I, Zacher B, Eckmanns T, Werner G, Willrich N, Haller S. 2022. Germany's Burden of Disease of Bloodstream Infections Due to Vancomycin-Resistant Enterococcus faecium between 2015–2020. Microorganisms 10:2273. https://doi.org/10.3390/microorganisms10112273.

9. Vehreschild MJGT, Haverkamp M, Biehl LM, Lemmen S, Fätkenheuer G. 2019. Vancomycin-resistant enterococci (VRE): a reason to isolate? Infection 47:7–11. https://doi.org/10.1007/s15010-018-1202-9.

10. Jünemann S, Sedlazeck FJ, Prior K, Albersmeier A, John U, Kalinowski J, Mellmann A, Goesmann A, Von Haeseler A, Stoye J, Harmsen D. 2013. Updating benchtop sequencing performance comparison. Nat Biotechnol 31:294–296. https://doi.org/10.1038/nbt.2522.

11. Werner G, Neumann B, Weber RE, Kresken M, Wendt C, Bender JK, Becker K, Borgmann S, Diefenbach A, Hamprecht A, Hogardt M, Wichelhaus T, Kemp V, Huebner N-O, Kaasch A, Geginat G, Kohnen W, Menzer A, Krause T, Miethke T, Pranada F, Radojn F, Tobisch S, Jansen V, Regnath T, Bührlen U, Schneider-Brachert W, Schwarz R, Luemen M, Skov R, Thuermer A, Baum HV, Weig M, Uwe G, Zabel L, Wulffen HV, Döring S. 2020. Thirty years of VRE in Germany – "expect the unexpected": The view from the National Reference Centre for Staphylococci and Enterococci. Drug Resist Updat 53:100732. https://doi.org/10.1016/j.drup.2020.100732.

12. Bender JK, Hermes J, Zabel LT, Haller S, Mürter N, Blank H-P, Werner G, Hüttner I, Eckmanns T. 2022. Controlling an Unprecedented Outbreak with Vancomycin-Resistant Enterococcus

faecium in Germany, October 2015 to November 2019. Microorganisms 10:1603. https://doi.org/10.3390/microorganisms10081603.

13. Chanumolu SK, Albahrani M, Otu HH. 2019. FQStat: a parallel architecture for very high-speed assessment of sequencing quality metrics. BMC Bioinformatics 20:424. https://doi.org/10.1186/s12859-019-3015-y.

14. Deneke C, Brendebach H, Uelze L, Borowiak M, Malorny B, Tausch SH. 2021. Species-Specific Quality Control, Assembly and Contamination Detection in Microbial Isolate Sequences with AQUAMIS. Genes 12:644. https://doi.org/10.3390/genes12050644.

15. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing. J Comput Biol 19:455–477. https://doi.org/10.1089/cmb.2012.0021.

16. De Been M, Pinholt M, Top J, Bletz S, Mellmann A, Van Schaik W, Brouwer E, Rogers M, Kraat Y, Bonten M, Corander J, Westh H, Harmsen D, Willems RJL. 2015. Core Genome Multilocus Sequence Typing Scheme for High-Resolution Typing of Enterococcus faecium. J Clin Microbiol 53:3788–3797. https://doi.org/10.1128/JCM.01946-15.

17. Harris SR. 2018. SKA: Split Kmer Analysis Toolkit for Bacterial Genomic Epidemiology. 453142. bioRxiv https://doi.org/10.1101/453142.

18. Gastmeier P, Schroder C, Behnke M, Meyer E, Geffers C. 2014. Dramatic increase in vancomycin-resistant enterococci in Germany. J Antimicrob Chemother 69:1660–1664. https://doi.org/10.1093/jac/dku035.

19. Remschmidt C, Schröder C, Behnke M, Gastmeier P, Geffers C, Kramer TS. 2018. Continuous increase of vancomycin resistance in enterococci causing nosocomial infections in Germany − 10 years of surveillance. Antimicrob Resist Infect Control 7:54. https://doi.org/10.1186/s13756-018-0353-x.

20. Xanthopoulou K, Peter S, Tobys D, Behnke M, Dinkelacker AG, Eisenbeis S, Falgenhauer J, Falgenhauer L, Fritzenwanker M, Gölz H, Häcker G, Higgins PG, Imirzalioglu C, Käding N, Kern WV, Kramme E, Kola A, Mischnik A, Rieg S, Rohde AM, Rupp J, Tacconelli E, Vehreschild MJGT, Walker SV, Gastmeier P, Seifert H, the DZIF R-Net Study Group, Bader B, Foschi F, Gillis M, Hennelly C, Hoffmann N, Hölzl F, Lengler A, Lenke D, Diaz LAP, Peyerl-Hoffmann G, Pilarski G, Proske S, Schmiedel J, Spitznagel H, Stelzer Y, Thoma N, Trauth J, Vavra M, Weber A, Wille J, Bader B, Foschi F, Gillis M, Hennelly C, Hoffmann N, Hölzl F, Lengler A, Lenke D, Diaz LAP, Peyerl-Hoffmann G, Pilarski G, Proske S, Schmiedel J, Spitznagel H, Stelzer Y, Thoma N, Trauth J, Vavra M, Weber A, Wille J. 2020. Vancomycin-resistant Enterococcus faecium colonizing patients on hospital admission in Germany: prevalence and molecular epidemiology. J Antimicrob Chemother 75:2743–2751. https://doi.org/10.1093/jac/dkaa271.

21. Weber A, Maechler F, Schwab F, Gastmeier P, Kola A. 2020. Increase of vancomycin-resistant Enterococcus faecium strain type ST117 CT71 at Charité - Universitätsmedizin Berlin, 2008 to 2018. Antimicrob Resist Infect Control 9:109. https://doi.org/10.1186/s13756-020-00754-1.

22. Rhine-Main VREfm study group, Falgenhauer L, Fritzenwanker M, Imirzalioglu C, Steul K, Scherer M, Heudorf U, Chakraborty T. 2019. Near-ubiquitous presence of a vancomycin-resistant Enterococcus faecium ST117/CT71/vanB –clone in the Rhine-Main metropolitan area of Germany. Antimicrob Resist Infect Control 8:128. https://doi.org/10.1186/s13756-019-0573-8.

23. Cimen C, Berends MS, Bathoorn E, Lokate M, Voss A, Friedrich AW, Glasner C, Hamprecht A. 2023. Vancomycin-resistant enterococci (VRE) in hospital settings across European borders: a scoping review comparing the epidemiology in the Netherlands and Germany. Antimicrob Resist Infect Control 12:78. https://doi.org/10.1186/s13756-023-01278-0.

24. Permana B, Harris PNA, Runnegar N, Lindsay M, Henderson BC, Playford EG, Paterson DL, Beatson SA, Forde BM. 2023. Using Genomics To Investigate an Outbreak of Vancomycin-

Resistant Enterococcus faecium ST78 at a Large Tertiary Hospital in Queensland. Microbiol Spectr 11:e04204-22. https://doi.org/10.1128/spectrum.04204-22.

25. Hammerum AM, Karstensen KT, Roer L, Kaya H, Lindegaard M, Porsbo LJ, Kjerulf A, Pinholt M, Holzknecht BJ, Worning P, Nielsen KL, Hansen SGK, Clausen M, Søndergaard TS, Dzajic E, Østergaard C, Wang M, Koch K, Hasman H. 2024. Surveillance of vancomycin-resistant enterococci reveals shift in dominating clusters from vanA to vanB Enterococcus faecium clusters, Denmark, 2015 to 2022. Eurosurveillance 29. https://doi.org/10.2807/1560-7917.ES.2024.29.23.2300633.

26. Hornuss D, Göpel S, Walker SV, Tobys D, Häcker G, Seifert H, Higgins PG, Xanthopoulou K, Gladstone BP, Cattaneo C, Mischnik A, Rohde AM, Imirzalioglu C, Trauth J, Fritzenwanker M, Falgenhauer J, Gastmeier P, Behnke M, Kramme E, Käding N, Rupp J, Peter S, Schmauder K, Eisenbeis S, Kern WV, Tacconelli E, Rieg S, DZIF R.-N. E. T. Study Group, Peña Diaz LA, Pilarski G, Thoma N, Peyerl-Hoffmann G, Gölz H, Joost I, Mathé P, Gillis M, Vehreschild M, Wille J, Steffens B, Blum Y, Kleipass M, Lenke D, Herold S, Schmiedel J, Lengler A, Buhl M, Hölzl F, Dinkelacker A. 2024. Epidemiological trends and susceptibility patterns of bloodstream infections caused by Enterococcus spp. in six German university hospitals: a prospectively evaluated multicentre cohort study from 2016 to 2020 of the R-Net study group. Infection 52:1995–2004. https://doi.org/10.1007/s15010-024-02249-2.

27. Ayobami O, Willrich N, Reuss A, Eckmanns T, Markwart R. 2020. The ongoing challenge of vancomycin-resistant *Enterococcus faecium* and *Enterococcus faecalis* in Europe: an epidemiological analysis of bloodstream infections. Emerg Microbes Infect 9:1180–1193. https://doi.org/10.1080/22221751.2020.1769500.

28. Fischer MA, Bender JK, Kriebel N, Weber RE, Wohlfarth E, Maechler F, Noll I, Abu Sin M, Werner G. 2023. Eigenschaften, Häufigkeit und Verbreitung von Vancomycin-resistenten Enterokokken in Deutschland – Update. Epidemiol Bull 28:3–17. https://doi.org/10.25646/11609.

29. Mills EG, Hewlett K, Smith AB, Griffith MP, Pless L, Sundermann AJ, Harrison LH, Zackular JP, Van Tyne D. 2025. Bacteriocin production facilitates nosocomial emergence of vancomycin-resistant Enterococcus faecium. Nat Microbiol 10:871–881. https://doi.org/10.1038/s41564-025-01958-0.

30. Lee T, Pang S, Daley DA, Pearson JC, Abraham S, Coombs GW. 2022. The changing molecular epidemiology of Enterococcus faecium harbouring the van operon at a teaching hospital in Western Australia: A fifteen-year retrospective study. Int J Med Microbiol 312:151546. https://doi.org/10.1016/j.ijmm.2021.151546.

31. Van Tyne D, Gilmore MS. 2014. Friend Turned Foe: Evolution of Enterococcal Virulence and Antibiotic Resistance. Annu Rev Microbiol 68:337–356. https://doi.org/10.1146/annurev-micro-091213-113003.

32. Brinkwirth S, Feig M, Noll I, Eckmanns T, Dörre A, Haller S, Willrich N. 2025. Changing dynamics of bloodstream infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium in Germany, 2017–2023: a continued burden of disease approach. Antimicrob Resist Infect Control 14:4. https://doi.org/10.1186/s13756-025-01522-9.

33. Genath A, Hackmann C, Denkel L, Weber A, Maechler F, Kola A, Schwarz S, Gastmeier P, Leistner R. 2024. The genetic relationship between human and pet isolates: a core genome multilocus sequence analysis of multidrug-resistant bacteria. Antimicrob Resist Infect Control 13:107. https://doi.org/10.1186/s13756-024-01457-7.

34. Kampmeier S, Tönnies H, Correa-Martinez CL, Mellmann A, Schwierzeck V. 2020. A nosocomial cluster of vancomycin resistant enterococci among COVID-19 patients in an intensive care unit. Antimicrob Resist Infect Control 9:154. https://doi.org/10.1186/s13756-020-00820-8.

35. Rath A, Kieninger B, Caplunik-Pratsch A, Fritsch J, Mirzaliyeva N, Holzmann T, Bender JK, Werner G, Schneider-Brachert W. 2024. Concerning emergence of a new vancomycin-resistant

Enterococcus faecium strain ST1299/CT1903/vanA at a tertiary university centre in South Germany. J Hosp Infect 143:25–32. https://doi.org/10.1016/j.jhin.2023.10.008.

36. Kavanagh NL, Kinnevey PM, Egan SA, McManus BA, O'Connell B, Brennan GI, Coleman DC. 2024. Protracted transmission and persistence of ST80 vancomycin-resistant Enterococcus faecium clonal complex types CT2933, CT2932 and CT1916 in a large Irish hospital: a 39-month whole-genome sequencing study. J Hosp Infect 151:11–20. https://doi.org/10.1016/j.jhin.2024.06.002.

37. Hansen SGK, Roer L, Karstensen KT, Hoegh SV, Hansen F, Klein K, Rosenvinge FS, Holm A, Skov MN, Hammerum AM, Hasman H. 2023. Vancomycin-sensitive Enterococcus faecium bacteraemia – hospital transmission and mortality in a Danish University Hospital. J Med Microbiol 72. https://doi.org/10.1099/jmm.0.001731.

38. Lehmkuhl J, Schneider JS, Werth KLV, Scherff N, Mellmann A, Kampmeier S. 2024. Role of membrane vesicles in the transmission of vancomycin resistance in Enterococcus faecium. Sci Rep 14:1895. https://doi.org/10.1038/s41598-024-52310-1.

39. Sobkowiak A, Scherff N, Van Almsick V, Schuler F, Brix TJ, Mellmann A, Schwierzeck V. 2025. Characterization of vanA-harboring plasmids supports differentiation of outbreak-related and sporadic vancomycin-resistant Enterococcus faecium isolates in a tertiary care hospital. BMC Microbiol 25:337. https://doi.org/10.1186/s12866-025-04058-5.

40. Higgs C, Sherry NL, Seemann T, Horan K, Walpola H, Kinsella P, Bond K, Williamson DA, Marshall C, Kwong JC, Grayson ML, Stinear TP, Gorrie CL, Howden BP. 2022. Optimising genomic approaches for identifying vancomycin-resistant Enterococcus faecium transmission in healthcare settings. Nat Commun 13:509. https://doi.org/10.1038/s41467-022-28156-4.

41. Caplunik-Pratsch A, Kieninger B, Donauer VA, Brauer JM, Meier VMK, Seisenberger C, Rath A, Loibl D, Eichner A, Fritsch J, Schneider-Brachert W. 2024. Introduction and spread of vancomycin-resistant Enterococcus faecium (VREfm) at a German tertiary care medical center from 2004 until 2010: a retrospective whole-genome sequencing (WGS) study of the molecular epidemiology of VREfm. Antimicrob Resist Infect Control 13:20. https://doi.org/10.1186/s13756-024-01379-4.

42. Bayjanov JR, Baan J, Rogers MRC, Troelstra A, Willems RJL, Van Schaik W. 2019. Enterococcus faecium genome dynamics during long-term asymptomatic patient gut colonization. Microb Genomics 5. https://doi.org/10.1099/mgen.0.000277.

43. Maechler F, Weber A, Schwengers O, Schwab F, Denkel L, Behnke M, Gastmeier P, Kola A. 2023. Split k-mer analysis compared to cgMLST and SNP-based core genome analysis for detecting transmission of vancomycin-resistant enterococci: results from routine outbreak analyses across different hospitals and hospitals networks in Berlin, Germany. Microb Genomics 9. https://doi.org/10.1099/mgen.0.000937.

44. Jochim-Vukosavic A, Schwab F, Knegendorf L, Schlüter D, Bange F-C, Ebadi E, Baier C. 2024. Epidemiology and infection control of vancomycin-resistant enterococci at a German university hospital: A three-year retrospective cohort study. PLOS ONE 19:e0297866. https://doi.org/10.1371/journal.pone.0297866.

45. Wagenvoort JHT, De Brauwer EIGB, Penders RJR, Willems RJ, Top J, Bonten MJ. 2011. Environmental survival of vancomycin-resistant Enterococcus faecium. J Hosp Infect 77:282–283. https://doi.org/10.1016/j.jhin.2010.11.008.

Figures

Figure 1: Patients with VRE at Hannover Medical School from 2013 to 2024_1. Number of patients with VanA- (dashed line) and VanB-phenotype (solid line) VRE per half-year from 2013 to 2024_1. Annual total case counts are shown as a light blue area.

Figure 2: Overview of the isolates analyzed in this study. (A) Flowchart depicting the selection process of *E. faecium* isolates from BSIs. Exclusions due to unavailability, quality control issues, and duplicate cases are indicated, along with the stratification of isolates into *vanA*-, *vanB*-, and *van*-negative genotypes. **(B)** Proportion of isolates included in the final analysis relative to the total number of isolates meeting the inclusion criteria separated by year.

Figure 3: Characterization and temporal distribution of invasive VRE isolates at Hannover Medical School from 2017_2 to 2022_1. (A) Number of isolates per half-year, categorized by ST and CT. **(B)** Proportion of isolates assigned to each ST/CT over time. **(C)** Proportion of isolates with *vanA*, *vanB*, and *van*-negative genotypes over time. **(D)** Total number of isolates for each ST/CT, stratified by *vanA*, *vanB*, and *van*-negative genotypes.

Figure 4: MST of invasive VRE isolates collected from 2017_2 to 2022_1 at Hannover Medical School. The MST was inferred based on cgMLST applying the “pairwise ignore missing values” option. **(A)** Distribution of STs and CTs. Clusters (shown in dark gray) were defined using a pairwise allelic difference threshold of ≤15 alleles and are numbered by ascending size. **(B)** Distribution of *van* genotypes: *vanA* (gray), *vanB* (black), *van*-negative (white).

Figure 5: Hierarchical classification of *E. faecium* isolates based on different typing methods. CgMLST clusters were defined using a pairwise allelic difference threshold of ≤15 alleles. SKA clusters were defined by a 7-SNP threshold. Connecting lines indicate how individual isolates are assigned across typing methods. Node size corresponds to the number of isolates per category, and node labels indicate ST, CT, or cluster number, as designated by the column-specific headers above each group of nodes.

Figure 6: Identification of epidemiological links in SKA-defined outbreak clusters. (A) Sankey diagram illustrating how cgMLST cluster 2 partitions into distinct SKA clusters and singletons. **(B)** Visualization of epidemiological connections within SKA clusters. The colors of the circles represent the year of isolation. Lines indicate patient contact categories, based on defined ward-level overlaps.


Resistance phenotype E. faecium VRE
VanB
VanA
Number of patients (lines)
Number of treated cases (area)
1,000
800
600
400
200
0
65,000
60,000
55,000
50,000
2013_1
2013_2
2014_1
2014_2
2015_1
2015_2
2016_1
2016_2
2017_1
2017_2
2018_1
2018_2
2019_1
2019_2
2020_1
2020_2
2021_1
2021_2
2022_1
2022_2
2023_1
2023_2
2024_1
Half-year

A

414 *E. faecium* isolates from blood cultures with AST data

68 isolates not stored
2 isolates used for testing of sequencing platform

344 isolates sequenced

11 isolates excluded due to inadequate QC parameters

333 isolates included in analysis

van negative N=**238**

vanA N=**19**

vanB N=**76**

32 isolates excluded (same patient and CT)

2 isolates excluded (same patient and CT)

10 isolates excluded (same patient and CT)

duplicate exclusion for population analysis

van negative adjusted for duplicates N=**206**

vanA adjusted for duplicates N=**17**

vanB adjusted for duplicates N=**66**

B




A
Number of isolates
Half-year
2017_2
2018_1
2018_2
2019_1
2019_2
2020_1
2020_2
2021_1
2021_2
2022_1
other
ST80
ST262
other
CT929
CT2035
CT2505
CT36
CT1917
CT71
ST117
B
Proportion of isolates (%)
Half-year
C
Proportion of isolates (%)
vanA
vanB
van negative
Half-year
D
other
ST80
ST262
other ST117
CT929
CT2035
CT2505
CT36
CT1917
CT71
vanA
vanB
van negative
Number of isolates


A
ST80
ST262
ST117
other
ST80
ST262
other
CT929
CT2035
CT2505
CT36
CT1917
CT71
ST117
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
B
ST80
ST262
ST117
vanA
vanB
van negative


ST
CT
cgMLST Cluster
SKA Cluster
117
80
262
other
929
2505
71
2035
36
1917
7839
other
467
1470
other
1894
2923
other
other
1
2
3
4
5 - 20
single-
tons
1 - 40
single-
tons


A
SKA Cluster
cgMLST Cluster
2
n=54
11
n=4
12
n=4
13
n=3
14
n=3
15
n=3
16
n=2
17
n=2
18
n=2
Singletons
n=31
B
Cluster 11
Cluster 12
Cluster 13
Cluster 14
Cluster 15
Cluster 16
Cluster 17
Cluster 18
2017
2018
2019
2021
Year
same patient
same ward/ within 30 days
same ward/ >30 days apart